Condition: Heart Failure With Preserved Ejection Fraction · Sponsor: Indiana University
The objective of this pilot study is to establish evidence to support the validity of HT in improving skeletal muscle function and physical capacity of patients with HFpEF. Our central hypothesis is that HT treatment will lead to improvements in skeletal muscle and microvascular function compared to a control intervention. As a result, we anticipate that patients treated with HT will demonstrate improved skeletal muscle microvascular blood flow and oxygenation resulting in enhanced exercise tolerance. To explore this hypothesis, we propose the following specific aim: Explore the effects of home-based HT on exercise tolerance in patients with HFpEF.
This description comes directly from the study's public registry record.
Doris Muriathiri, MPH, CCRP · 317-274-0903 · dmuriath@iu.edu
Daniel Hirai, PhD · 765-494-7113 · dhirai@purdue.edu
Always discuss trial participation with your own doctor first.
| IU Health Methodist | Indianapolis, Indiana, United States | Recruiting |
| IU Health University Hospital | Indianapolis, Indiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06388226